SecBot SecBot
PRESS-RELEASE ·Filed Mar 3, 2026

CERT

Certara
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should view this as a strong validation of Certara's technology platform, likely to enhance commercial credibility and drive adoption across biopharma clients. Monitor for follow-on announcements regarding new client engagements or expanded use of Simcyp in other NDAs.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.24
T+0 close · Mar 3, 2026 · via day close
Latest settled
−26.11%
T+60 · $5.35
Vs SPY
−36.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 3 $7.24entry
  2. T+1 · 9mo ago +1.52%α +0.76% · $7.35
  3. T+5 · 8mo ago −4.28%α −3.80% · $6.93
  4. T+20 · 8mo ago −21.27%α −16.87% · $5.70
  5. T+60 · 6mo ago −26.11%α −36.42% · $5.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Certara announced that its Simcyp® Simulator was used to support the FDA's acceptance of PBPK modeling in lieu of clinical studies for the approval of asciminib (Scemblix®), a first-in-class treatment for Chronic Myeloid Leukemia. This marks a significant regulatory validation of Certara's model-informed drug development technology, highlighting its ability to replace at least ten clinical pharmacology studies and streamline the NDA process.

Key Facts

  • FDA accepted PBPK modeling via Certara's Simcyp Simulator in lieu of clinical studies for asciminib (Scemblix®) NDA approval.
  • Modeling replaced at least ten dedicated clinical pharmacology studies.
  • Asciminib is a first-in-class allosteric inhibitor for Chronic Myeloid Leukemia (CML).
  • Simcyp's modeling supported dosing regimens and drug interaction profiles across diverse populations.
  • Novartis, a Simcyp Consortium member, led the modeling work in collaboration with Certara.

Financial Impact

Significant long-term revenue potential as regulatory acceptance strengthens demand for Certara’s biosimulation tools; validation could lead to broader adoption and expanded contracts.

revenuemarket shareclient acquisition

Risk Factors

  • Revenue impact may be delayed as adoption cycles in biopharma are long.
  • Success depends on continued regulatory acceptance beyond this single case.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Software & IT

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3248265

Track record

14 reports on CERT

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +51.56% at T+60 after the Aug 15, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $12.22 to $12.13 Now $11.39 −6.79% ▼ −0.78% −0.41% vs SPY
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $12.18 to $12.05 Now $11.39 −6.49% ▼ −1.07% −1.38% vs SPY
  4. Aug 15, 202613w ago Institutional Cluster Bullish 5/10 Entry $8.00 to $8.01 Now $11.39 +42.38% ▲ +0.13% +0.80% vs SPY
  5. Aug 4, 202614w ago 8-K Neutral 2/10 Entry $7.80 to $8.01 Now $11.39 +46.03% ▲ +2.69% +2.89% vs SPY
  6. Jul 15, 202617w ago Press Release Neutral 1/10 Entry $7.28 to $6.93 Now $11.39 +56.46% ▼ −4.81% −3.82% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $5.27 to $5.20 Now $11.39 −116.13% ▲ +1.33% +1.87% vs SPY
  8. May 11, 202627w ago 8-K Bearish 6/10 No price data
  9. May 11, 202627w ago Press Release Bearish 7/10 Entry $5.13 to $5.09 Now $11.39 −122.03% ▲ +0.78% +0.64% vs SPY
  10. Apr 22, 202629w ago 8-K / PRESS-RELEASE Bullish 7/10 Entry $6.38 to $6.00 Now $11.39 +78.53% ▼ −5.96% −5.56% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (9h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026